StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a report released on Wednesday morning. The firm issued a sell rating on the stock.
Oragenics Stock Performance
OGEN opened at $0.40 on Wednesday. The firm has a market cap of $1.78 million, a price-to-earnings ratio of -0.05 and a beta of 0.50. The firm’s 50-day simple moving average is $0.92 and its 200-day simple moving average is $1.26. Oragenics has a twelve month low of $0.38 and a twelve month high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.
Institutional Investors Weigh In On Oragenics
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- Using the MarketBeat Stock Split Calculator
- CarMax’s Impressive Rally: What Investors Should Watch Next
- The Most Important Warren Buffett Stock for Investors: His Own
- MarketBeat Week in Review – 9/23 – 9/27
- What Investors Need to Know About Upcoming IPOs
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.